HIV vaccine candidate moves to human safety tests

NCT ID NCT04177355

Completed ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 1 trial tested an experimental HIV vaccine in 127 healthy, HIV-uninfected adults. The vaccine uses a protein called BG505 SOSIP.664 gp140 combined with various adjuvants to boost immune response. The main goal was to check safety and how well the vaccine triggers an immune reaction. Results will help decide if further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HIV-1 BG505 SOSIP.664 gp140 vaccine with adjuvants (TLR agonist, alum, 3M-052-AF, CpG 1018, GLA-LSQ, Trimer 4571)
What this could lead to: If successful, this could point toward a safe and effective HIV vaccine that prevents infection.
What could go wrong: This is an early Phase 1 trial focused on safety and immune response, not on preventing HIV. The vaccine may not produce strong enough immunity or could have side effects. Many HIV vaccine candidates have failed in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Alabama CRS

Birmingham, Alabama, 35294, United States
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)

Boston, Massachusetts, 02115-6110, United States
Columbia P&S CRS

New York, New York, 10032, United States
New York Blood Center CRS (Site 31801)

New York, New York, 10065, United States
Penn Prevention CRS

Philadelphia, Pennsylvania, 19104, United States
Seattle Vaccine and Prevention CRS

Seattle, Washington, 98109-1024, United States
The Hope Clinic of the Emory Vaccine Center CRS

Decatur, Georgia, 30030, United States
The Ponce de Leon Center CRS

Atlanta, Georgia, 30308-2012, United States
University of Pittsburgh CRS

Pittsburgh, Pennsylvania, 15213, United States
University of Rochester Vaccines to Prevent HIV Infection CRS

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.